Generic Name: ixekizumab
Brand Name: Taltz
Manufacturer: Eli Lilly Canada Inc.
Indications: Ankylosing spondylitis
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to, or are intolerant to conventional therapy.
Submission Type: New Indication
Project Status: Pending
Call For Patient Input: August 1, 2019
Patient Input Closed: September 23, 2019
Anticipated Date: August 30, 2019
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.